CLINCH-3NCT07795346
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Trial sites expanded: 114 → 131 locations
- Start date changed from estimate of Sep 1, 2026 to Sep 17, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression-Free Survival(PFS )
Timeframe: From randomization to first PD or death. Tumour assessments at baseline, q6w (±1w) during treatment, q12w (±1w) after 12m, q24w (±1w) after 24m, until PD/death/study end (~228 OS events, ~1yr after LPI).
Overall Survival(OS)
Timeframe: From randomization to death. Survival follow-up q3m (±14d) until death/study termination (~228 OS events).
Secondary (3)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)
Arms and interventions
ATG-022Experimental
Docetaxel or IrinotecanActive comparator
Drugs: ATG-022, Docetaxel or Irinotecan
Sites
131 sites in 1 country